Global Gout Therapeutics Market
Sizing, Segmentation, & Growth Forecast (2025-2030)
Last updated: August 2026
Report Scope: The downloadable datasheet contains market sizes in USD for the period 2025-30.
Market Breakdown: Sizes and growth rates are broken down by geography and market segment (see below for details).
1. Summary
The Global Gout Therapeutics Market was valued at $3.4 bn. in 2025. During the forecast period 2025-2030, it is expected to grow at 7.8% CAGR, to an estimated market size of $4.9 bn. in 2030. A detailed breakdown by segment and geography is provided in the downloadable datasheet.
2. Market Definition
The global gout therapeutics market includes pharmacological treatments and management strategies for gout, a form of inflammatory arthritis caused by hyperuricemia. The scope covers urate-lowering therapies (ULTs) such as xanthine oxidase inhibitors and uricosurics, anti-inflammatory agents like NSAIDs, colchicine, and corticosteroids, and biologic therapies (e.g., IL-1 inhibitors) used for acute flare management and chronic disease control.
3. Trends & Demand Drivers
Several key trends are expected to significantly impact the Gout Therapeutics Market in the period 2025-30:
- The rising global prevalence of metabolic syndrome, obesity, and sedentary lifestyles is significantly increasing the patient pool for gout therapeutics.
- Clinical practice is shifting toward a treat-to-target approach, emphasizing long-term serum urate reduction rather than just reactive flare management.
- Increased R&D investment is flowing into biologic therapies and interleukin-1 (IL-1) inhibitors to address the needs of patients with refractory or chronic tophaceous gout.
- The integration of precision medicine and genetic screening, such as HLA-B*5801 testing, is enabling safer and more personalized dosing of xanthine oxidase inhibitors.
- The adoption of digital health tools and AI-based monitoring platforms is improving patient adherence to chronic urate-lowering medication regimens.
- Rapid urbanization and dietary shifts in emerging markets, particularly China and India, are making the Asia-Pacific region the primary engine for market growth.
- The market is facing challenges from cardiovascular safety warnings associated with certain established medications, prompting a search for safer alternative mechanisms.
4. Market Breakdown
The downloadable datasheet breaks market sizes and growth rates (CAGRs) down into the following geographies and segments:
Geographies
- North America
- Europe
- Asia-Pacific
- Rest of World
Segments
- Urate-Lowering Therapy (ULT)
- NSAIDs
- Others (Colchicine, Biologics, Steroids)